Showing results (201-210 of 340) with videos related to
Sort By:
Pageof 34
Diabetes Care|January 13, 2017
Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 DiabetesGert Mayer, Hiddo J L Heerspink, Constantin Aschauer, et al.The Lancet. Diabetes & Endocrinology|June 26, 2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsVlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, et al.Journal of the American Society of Nephrology : JASN|September 30, 2003
Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic populationSara-Joan Pinto-Sietsma, Stefan-Martin Herrmann, Klaus Schmidt-Petersen, et al.Kidney International. Supplement|December 23, 2004
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuriaAndrew J Palmer, Lieven Annemans, Stéphane Roze, et al.Circulation|November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.Journal of the American Society of Nephrology : JASN|May 4, 2007
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney diseaseDavid M Kent, Tazeen H Jafar, Rodney A Hayward, et al.Journal of the American Society of Nephrology : JASN|May 6, 2005
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang, Shahnaz Shahinfar, William F Keane, et al.Kidney International|May 3, 2014
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesMark E Molitch, Amanda I Adler, Allan Flyvbjerg, et al.Journal of the American Society of Nephrology : JASN|January 18, 2008
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathyHans-Henrik Parving, Dick de Zeeuw, Mark E Cooper, et al.Diabetes, Obesity & Metabolism|August 17, 2021
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysisKent Y Feng, JingWei Li, Juliana Ianus, et al.Pageof 34